SMARCA4 and glioblastoma: Since we found that IV‐255 has high selectivity for the BRG1 bromodomain, it would be of interest to develop a PROTAC based on the IV‐255 structure to target the BRG1 bromodomain as a novel therapeutic strategy for GBM in the future.